Caris Life Sciences, Inc.: updates and filings

CAINASDAQHealthcare · Services-Medical Laboratories

Price

$18.54

November 19, 2026Market cap $5.2B

What Ploutos Investor adds for Caris Life Sciences

Part of Ploutos Investor, €9.99 a month

See the plans
  • The full history: 3 fiscal years, from 2023
  • The estimated fair value, with its range and its certainty
  • The full analysis, 18 a month
  • More questions to the chat on its filings
  • Excel with every year
  • An email when it reports, changes its dividend or an officer buys

Sign in with a free account to see the last 5 fiscal years.

Notes on these figures

  • The share price has fallen 41% since Nov 4, 2026, when the 10-Q these figures come from was filed ($33.22 then, $19.50 on Nov 18, 2026). The figures date from before that move.10-Q
  • The interest the company pays is far more than the debt we can read would cost, so part of its borrowing is missing from the figures. We leave out the debt, net cash, enterprise value and the multiples built on them.

What comes next, and what happened

Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.

Next results

in 77 daysAround Feb 5, 2027 · for Q4 2026

last Nov 4, 2026next Feb 5, 2027

An estimate from when it has reported before, which has been regular. The company announces the date itself.

Its SEC filings

What it has filed lately, newest first, linked to the document itself.

Mar 3, 2026 latest annualNov 4, 2026 latest quarterly
  • Nov 5, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026
    Form10-Q
  • Nov 4, 2026Results of operations
    Form8-K
  • Sep 14, 2026Regulation FD disclosure
    Form8-K
  • Aug 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Aug 5, 2026Quarterly reportfor the period to Jun 30, 2026
    Form10-Q
  • Aug 5, 2026Results of operations
    Form8-K
  • Jun 16, 2026Exchange certification of a listing
    FormCERT
  • Jun 16, 2026Securities listed on an exchange
    Form8-A12B
  • Jun 5, 2026Shareholder vote
    Form8-K
  • May 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 12, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • May 8, 2026Quarterly reportfor the period to Mar 31, 2026
    Form10-Q
  • May 7, 2026Results of operations
    Form8-K
  • Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025
    FormARS
  • Apr 23, 2026Additional annual meeting material
    FormDEFA14A
  • Apr 23, 2026Annual meeting proxy statement
    FormDEF 14A
  • Apr 7, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Apr 2, 2026Material agreement entered, material agreement ended, new material financial obligation
    Form8-K
  • Mar 3, 2026Annual reportfor the period to Dec 31, 2025
    Form10-K
  • Feb 26, 2026Results of operations, Regulation FD disclosure
    Form8-K
  • Feb 13, 2026Over-5% holder statement (passive) (amendment)
    FormSCHEDULE 13G/A
  • Feb 5, 2026Over-5% holder statement (passive)
    FormSCHEDULE 13G
  • Jan 12, 2026Results of operations, Regulation FD disclosure
    Form8-K

From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Jun 10, 2024.

The full analysis

What do Caris Life Sciences's filings show?

The filings are where every one of Caris Life Sciences's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.

  • A fair value range built from the filings
  • Earnings quality, debt and red flags
  • Insider and institutional moves
  • The case for and the case against

All filings on EDGAR

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.